Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JEREMIAH BROWN

Allopathic & Osteopathic Physicians Ophthalmology Retina Specialist

NPI
1891702163
CMS profile
86160
Location
SCHERTZ, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$99,457.51

141 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 3 of 3; records 101–141 of 141 matching records. This page contains 41 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JEREMIAH BROWN

NPI 1891702163 · CMS profile ID 86160

Allopathic & Osteopathic Physicians / Ophthalmology / Retina Specialist

SCHERTZ, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–141 of 141 matching records. This page contains 41 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1891702163?year=2024&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JEREMIAH BROWN, NPI 1891702163, CMS profile ID 86160. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–141 of 141 matching records. This page contains 41 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1891702163?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). JEREMIAH BROWN, NPI 1891702163, CMS profile ID 86160. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–141 of 141 matching records. This page contains 41 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1891702163?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
JEREMIAH BROWN, NPI 1891702163, CMS profile ID 86160, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–141 of 141 matching records. This page contains 41 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1891702163?year=2024&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

141 matching records · $99,457.51 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 141 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–141 of 141.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Biogen, Inc. $18.5804/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104813293 CMS
Harrow Eye, LLC $30.7504/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145599115 CMS
Genentech USA, Inc. $15.1004/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133031525 CMS
Regeneron Pharmaceuticals, Inc. $73.0604/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114396906 CMS
Astellas Pharma US Inc $450.0004/02/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139449686 CMS
ABBVIE INC. $26.5503/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103377413 CMS
Astellas Pharma US Inc $450.0003/18/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139449684 CMS
BIOTISSUE HOLDINGS INC. $123.9003/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148781531 CMS
Astellas Pharma US Inc $6,300.0003/14/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139449706 CMS
Astellas Pharma US Inc $40.0003/14/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139453670 CMS
Apellis Pharmaceuticals, Inc. $4,904.5003/13/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154022783 CMS
Astellas Pharma US Inc $150.0003/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139307814 CMS
Apellis Pharmaceuticals, Inc. $202.1003/07/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154022761 CMS
Apellis Pharmaceuticals, Inc. $210.4503/07/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154022781 CMS
Astellas Pharma US Inc $116.1603/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139449736 CMS
Astellas Pharma US Inc $1,081.2803/06/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139453668 CMS
Medline Industries LP $12.5903/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144136428 CMS
Genentech USA, Inc. $142.9903/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133031521 CMS
Regeneron Healthcare Solutions, Inc. $20.7903/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114015484 CMS
Medline Industries LP $8.7902/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144136426 CMS
Regeneron Healthcare Solutions, Inc. $140.5802/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114015482 CMS
Amgen Inc. $121.6302/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111537852 CMS
Genentech USA, Inc. $27.1802/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133031577 CMS
Biogen, Inc. $14.8702/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104876204 CMS
Astellas Pharma US Inc $7,650.0002/12/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139414037 CMS
Astellas Pharma US Inc $90.9202/12/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139452978 CMS
Astellas Pharma US Inc $13.1402/12/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139453120 CMS
Astellas Pharma US Inc $55.1202/12/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139453138 CMS
Apellis Pharmaceuticals, Inc. $3,750.5002/07/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154022751 CMS
Apellis Pharmaceuticals, Inc. $1,240.2401/31/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154022755 CMS
Apellis Pharmaceuticals, Inc. $121.5201/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154022763 CMS
Apellis Pharmaceuticals, Inc. $224.6401/31/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154022785 CMS
ABBVIE INC. $25.1201/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103377411 CMS
Astellas Pharma US Inc $103.9201/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139414301 CMS
Astellas Pharma US Inc $451.2001/25/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139453154 CMS
Apellis Pharmaceuticals, Inc. $1,500.0001/23/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154022779 CMS
Medline Industries LP $15.8701/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144136424 CMS
Alcon Vision LLC $140.0401/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110657365 CMS
Apellis Pharmaceuticals, Inc. $31.6901/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154022741 CMS
Medline Industries LP $7.5401/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144136376 CMS
ABBVIE INC. $132.6601/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103377409 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $31,163.26 50
PY2020 $7,132.01 20
PY2021 $36,672.38 44
PY2022 $39,226.32 44
PY2023 $50,051.29 90
PY2024 $99,457.51 141
PY2025 $75,091.82 90

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $9,801.12 12
PY2025 Principal investigator $1,461,674.89 564
PY2024 Recipient $9,919.04 9
PY2024 Principal investigator $426,491.13 98
PY2023 Recipient $49.95 1
PY2023 Principal investigator $524,548.49 107
PY2022 Principal investigator $262,983.85 25

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

576 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,444.55 12/23/2025 Non-covered Recipient Entity
Rctx-Texas Medical Center Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220803338
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/23/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184279804
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/23/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184279806
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/23/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184279808
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/23/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184279810
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 12/23/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184279812
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $162.00 12/23/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184279814
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 12/23/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184279816
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.25 12/23/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184279818
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/23/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184279820
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 12/23/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184279822
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/23/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184279824
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $162.00 12/23/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184279826
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 12/23/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184279828
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.25 12/23/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184279830
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $72,536.00 12/22/2025 Non-covered Recipient Entity
Rctx-Texas Medical Center Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220803336
Principal investigator 1 Genentech, Inc. $26.27 12/19/2025 Non-covered Recipient Entity
BROWN RETINA INSTITUTE
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211582251
Principal investigator 1 Genentech, Inc. $2,522.90 12/19/2025 Non-covered Recipient Entity
BROWN RETINA INSTITUTE
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211582255
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $60.76 12/19/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184278370
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4.34 12/19/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184278372
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $60.76 12/19/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184278374
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $60.24 12/19/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184278376
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 12/19/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184278378
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 12/19/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184278380
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 12/19/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184278382
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/19/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184278388
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/19/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184278390
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/19/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184278392
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/19/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184278394
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/19/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184278396
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/19/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184278398
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/19/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184278400
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/19/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184278402
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/19/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184278404
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/19/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184278406
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/19/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184278408
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/19/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184278410
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/19/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184278412
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/19/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184278414
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/19/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184278416
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/19/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184278418
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/19/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184278420
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/19/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184278422
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/19/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184278424
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/19/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184278426
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/19/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184278428
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/19/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184278430
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/19/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184278432
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/19/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184278434
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/19/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184278436
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/19/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184278438
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/19/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184278440
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/19/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184278442
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/19/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184278444
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/19/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184278446
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/19/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184278448
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/18/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184277468
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 12/18/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184277470
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.25 12/18/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184277472
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 12/18/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184277474
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 12/18/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184277496
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.25 12/18/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184277498
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 12/18/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184277500
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/18/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184277502
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $203.00 12/18/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184277520
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 12/18/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184277522
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $113.00 12/18/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184277524
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $155.25 12/18/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184277526
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $202.50 12/18/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184277528
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.25 12/18/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184277530
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $155.25 12/18/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184277532
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 12/18/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184277534
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 12/18/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184277536
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/18/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184277538
Principal investigator 1 F. Hoffmann-La Roche AG $75.00 12/17/2025 Non-covered Recipient Entity
Retina Consultants of Houston d/b/a Retina Consultants of Texas
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211644458
Principal investigator 1 Genentech, Inc. $3,257.00 12/17/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211644353
Principal investigator 1 Genentech, Inc. $78.19 12/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211644361
Principal investigator 1 ABBVIE INC. $162.00 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON PLLC
Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy (RGX-314 SRLTFU) No dispute reported 06/30/2026 1202530078
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $935.00 12/11/2025 Non-covered Recipient Entity
Rctx-Texas Medical Center Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220803332
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,000.00 12/11/2025 Non-covered Recipient Entity
Rctx-Texas Medical Center Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220803334
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,080.00 12/11/2025 Non-covered Recipient Entity
Rctx-Texas Medical Center Retina Center
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220803536
Principal investigator 1 Genentech, Inc. $796.00 12/10/2025 Non-covered Recipient Entity
BROWN RETINA INSTITUTE
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211582259
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $7,437.15 12/08/2025 Non-covered Recipient Entity
Rctx-Texas Medical Center Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220803328
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $676.00 12/08/2025 Non-covered Recipient Entity
Rctx-Texas Medical Center Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220803330
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $234.00 12/08/2025 Non-covered Recipient Entity
Rctx-Texas Medical Center Retina Center
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220803530
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $85.00 12/08/2025 Non-covered Recipient Entity
Rctx-Texas Medical Center Retina Center
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220803532
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $227.00 12/08/2025 Non-covered Recipient Entity
Rctx-Texas Medical Center Retina Center
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220803534
Principal investigator 1 ABBVIE INC. $17,282.00 12/04/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON PLLC
Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) No dispute reported 06/30/2026 1202527618
Principal investigator 1 Genentech, Inc. $2,897.00 12/03/2025 Non-covered Recipient Entity
BROWN RETINA INSTITUTE
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211582245
Principal investigator 1 Genentech, Inc. $16,094.00 12/03/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211644349
Principal investigator 1 Genentech, Inc. $9,910.00 12/03/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211644357
Principal investigator 1 Genentech, Inc. $1,524.00 12/03/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211644369
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 12/01/2025 Non-covered Recipient Entity
Retina Consultant Of Texas-Schertz Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220759231
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/01/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184267225
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/01/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184267227
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/01/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184267229
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/01/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184267231
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 12/01/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184267233
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 12/01/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184267235
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 12/01/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184267237
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 12/01/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184267239
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,404.00 11/25/2025 Non-covered Recipient Entity
Rctx-Texas Medical Center Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220803326
Principal investigator 1 Boehringer Ingelheim International GmbH $7,500.00 11/24/2025 Non-covered Recipient Entity
Retina Consultant Of Texas-Schertz Retina Center
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220759277
Principal investigator 1 Boehringer Ingelheim International GmbH $2,000.00 11/24/2025 Non-covered Recipient Entity
Retina Consultant Of Texas-Schertz Retina Center
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220759279
Principal investigator 1 Boehringer Ingelheim International GmbH $1,500.00 11/24/2025 Non-covered Recipient Entity
Retina Consultant Of Texas-Schertz Retina Center
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220759281
Principal investigator 1 Boehringer Ingelheim International GmbH $1,000.00 11/24/2025 Non-covered Recipient Entity
Retina Consultant Of Texas-Schertz Retina Center
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220759283
Principal investigator 1 Boehringer Ingelheim International GmbH $550.00 11/24/2025 Non-covered Recipient Entity
Retina Consultant Of Texas-Schertz Retina Center
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220759285
Principal investigator 1 Boehringer Ingelheim International GmbH $1,500.00 11/24/2025 Non-covered Recipient Entity
Retina Consultant Of Texas-Schertz Retina Center
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220759287
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 11/24/2025 Non-covered Recipient Entity
Retina Consultant Of Texas-Schertz Retina Center
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220759289
Principal investigator 1 Boehringer Ingelheim International GmbH $600.00 11/24/2025 Non-covered Recipient Entity
Retina Consultant Of Texas-Schertz Retina Center
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220759291
Principal investigator 1 Genentech, Inc. $17,090.50 11/19/2025 Non-covered Recipient Entity
BROWN RETINA INSTITUTE
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211582218
Principal investigator 1 Genentech, Inc. $78,705.00 11/19/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON PLLC RETINA CONSULTANTS OF TEXAS
Constance Faricimab in nAMD patients No dispute reported 06/30/2026 1211644791
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,053.00 11/13/2025 Non-covered Recipient Entity
Rctx-Texas Medical Center Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220803324
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,525.90 11/11/2025 Non-covered Recipient Entity
Rctx-Texas Medical Center Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220803316
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $100.00 11/11/2025 Non-covered Recipient Entity
Rctx-Texas Medical Center Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220803318
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $406.00 11/11/2025 Non-covered Recipient Entity
Rctx-Texas Medical Center Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220803320
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $170.00 11/11/2025 Non-covered Recipient Entity
Rctx-Texas Medical Center Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220803322
Principal investigator 1 Genentech, Inc. $3,887.36 11/07/2025 Non-covered Recipient Entity
BROWN RETINA INSTITUTE
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211582166
Principal investigator 1 Genentech, Inc. $876.00 11/07/2025 Non-covered Recipient Entity
BROWN RETINA INSTITUTE
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211582173
Principal investigator 1 Genentech, Inc. $796.00 11/07/2025 Non-covered Recipient Entity
BROWN RETINA INSTITUTE
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211582177
Principal investigator 1 Genentech, Inc. $183.00 11/07/2025 Non-covered Recipient Entity
BROWN RETINA INSTITUTE
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211582180
Principal investigator 1 Genentech, Inc. $613.00 11/07/2025 Non-covered Recipient Entity
BROWN RETINA INSTITUTE
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211582189
Principal investigator 1 Genentech, Inc. $796.00 11/07/2025 Non-covered Recipient Entity
BROWN RETINA INSTITUTE
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211582193
Principal investigator 1 Genentech, Inc. $796.00 11/07/2025 Non-covered Recipient Entity
BROWN RETINA INSTITUTE
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211582197
Principal investigator 1 Genentech, Inc. $796.00 11/07/2025 Non-covered Recipient Entity
BROWN RETINA INSTITUTE
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211582200
Principal investigator 1 Genentech, Inc. $230.00 11/07/2025 Non-covered Recipient Entity
BROWN RETINA INSTITUTE
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211582205
Principal investigator 1 Genentech, Inc. $2,556.68 11/07/2025 Non-covered Recipient Entity
BROWN RETINA INSTITUTE
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211582209
Principal investigator 1 Genentech, Inc. $613.00 11/07/2025 Non-covered Recipient Entity
BROWN RETINA INSTITUTE
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211582213
Principal investigator 1 Genentech, Inc. $22,657.50 11/07/2025 Non-covered Recipient Entity
BROWN RETINA INSTITUTE
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211582226
Principal investigator 1 Genentech, Inc. $66.76 11/07/2025 Non-covered Recipient Entity
BROWN RETINA INSTITUTE
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211582230
Principal investigator 1 Genentech, Inc. $1,226.00 11/07/2025 Non-covered Recipient Entity
BROWN RETINA INSTITUTE
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211582238
Principal investigator 1 Genentech, Inc. $183.00 11/07/2025 Non-covered Recipient Entity
BROWN RETINA INSTITUTE
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211582242
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $14,530.00 11/06/2025 Non-covered Recipient Entity
Rctx-Texas Medical Center Retina Center
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220803528
Principal investigator 1 Genentech, Inc. $613.00 11/05/2025 Non-covered Recipient Entity
BROWN RETINA INSTITUTE
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211582162
Principal investigator 1 Genentech, Inc. $183.00 11/05/2025 Non-covered Recipient Entity
BROWN RETINA INSTITUTE
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211582169
Principal investigator 1 Genentech, Inc. $613.00 11/05/2025 Non-covered Recipient Entity
BROWN RETINA INSTITUTE
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211582185
Principal investigator 1 Genentech, Inc. $1,999.47 11/05/2025 Non-covered Recipient Entity
BROWN RETINA INSTITUTE
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211582222
Principal investigator 1 Genentech, Inc. $4,528.30 11/05/2025 Non-covered Recipient Entity
BROWN RETINA INSTITUTE
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211582233
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 11/01/2025 Non-covered Recipient Entity
Retina Consultant Of Texas-Schertz Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220759229
Principal investigator 1 ABBVIE INC. $522.55 10/31/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON PLLC
Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy (RGX-314 SRLTFU) No dispute reported 06/30/2026 1202519941
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $879.00 10/30/2025 Non-covered Recipient Entity
Rctx-Texas Medical Center Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220803314
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $85.00 10/30/2025 Non-covered Recipient Entity
Rctx-Texas Medical Center Retina Center
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220803526
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/30/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184256187
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/30/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184256189
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/30/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184256191
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/30/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184256193
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/30/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184256195
Principal investigator 1 Genentech, Inc. $796.00 10/29/2025 Non-covered Recipient Entity
BROWN RETINA INSTITUTE
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211582134
Principal investigator 1 Genentech, Inc. $15,568.25 10/29/2025 Non-covered Recipient Entity
BROWN RETINA INSTITUTE
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211582142
Principal investigator 1 Genentech, Inc. $1,576.00 10/29/2025 Non-covered Recipient Entity
BROWN RETINA INSTITUTE
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211582158
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/29/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184255039
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/29/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184255041
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/29/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184255043
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/29/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184255045
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/29/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184255047
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/29/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184255049
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/29/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184255051
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/29/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184255053
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/29/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184255055
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/29/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184255057
Principal investigator 1 Hoffmann-La Roche Limited $553.00 10/24/2025 Non-covered Recipient Entity
RETINAL CONSULTANTS MEDICAL GROUP
A Phase I, Multi-center, Multi-part Study to Investigate Safety, Tolerability, PK, PD, and Immunogenicity of RO7669330 Intravitreal Injections in Participants With GA Secondary to AMD: Part 1A: Open-label, MAD; Part 1B: Randomized PD Pilot; Part 2: Masked, Randomized, Active-comparator-controlled No dispute reported 06/30/2026 1211646877
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $162.00 10/22/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184251948
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $162.00 10/22/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184251950
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $162.00 10/22/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184251952
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $162.00 10/22/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184251954
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $162.00 10/22/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184251956
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $162.00 10/22/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184251958
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $162.00 10/22/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184251960
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $162.00 10/22/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184251962
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $85.00 10/21/2025 Non-covered Recipient Entity
Rctx-Texas Medical Center Retina Center
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220803524
Principal investigator 1 Genentech, Inc. $1,839.00 10/17/2025 Non-covered Recipient Entity
BROWN RETINA INSTITUTE
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211582129
Principal investigator 1 Genentech, Inc. $12,000.00 10/15/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON PLLC RETINA CONSULTANTS OF TEXAS
Constance Faricimab in nAMD patients No dispute reported 06/30/2026 1211644783
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 10/15/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184250279
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 10/15/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184250281
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $510.00 10/13/2025 Non-covered Recipient Entity
Rctx-Texas Medical Center Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220803296
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,525.90 10/13/2025 Non-covered Recipient Entity
Rctx-Texas Medical Center Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220803298
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $7,437.15 10/13/2025 Non-covered Recipient Entity
Rctx-Texas Medical Center Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220803300
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,525.90 10/13/2025 Non-covered Recipient Entity
Rctx-Texas Medical Center Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220803302
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $118,733.00 10/09/2025 Non-covered Recipient Entity
Rctx-Texas Medical Center Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220803294
Principal investigator 1 Genentech, Inc. $5,845.01 10/03/2025 Non-covered Recipient Entity
BROWN RETINA INSTITUTE
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211582116
Principal investigator 1 Genentech, Inc. $796.00 10/03/2025 Non-covered Recipient Entity
BROWN RETINA INSTITUTE
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211582121
Principal investigator 1 Genentech, Inc. $397.99 10/03/2025 Non-covered Recipient Entity
BROWN RETINA INSTITUTE
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211582125
Principal investigator 1 Genentech, Inc. $1,987.18 10/03/2025 Non-covered Recipient Entity
BROWN RETINA INSTITUTE
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211582138
Principal investigator 1 Genentech, Inc. $796.00 10/03/2025 Non-covered Recipient Entity
BROWN RETINA INSTITUTE
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211582146
Principal investigator 1 Genentech, Inc. $1,132.00 10/03/2025 Non-covered Recipient Entity
BROWN RETINA INSTITUTE
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211582149
Principal investigator 1 Genentech, Inc. $666.00 10/03/2025 Non-covered Recipient Entity
BROWN RETINA INSTITUTE
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211582153
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,531.60 10/03/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184246085
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,531.60 10/03/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184246087
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/03/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184246123
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/03/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184246125
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/03/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184246127
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/03/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184246129
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/03/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184246131
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/03/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184246133
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/03/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184246135
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/03/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184246137
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/03/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184246139
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/03/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184246141
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/03/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184246143
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/03/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184246145
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 10/01/2025 Non-covered Recipient Entity
Retina Consultant Of Texas-Schertz Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220759227
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $69,122.00 10/01/2025 Non-covered Recipient Entity
Rctx-Texas Medical Center Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220803310
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $595.00 10/01/2025 Non-covered Recipient Entity
Rctx-Texas Medical Center Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220803312
Principal investigator 1 Genentech, Inc. $2,100.00 10/01/2025 Non-covered Recipient Entity
RETINA GROUP INC
A Phase IV, Multicenter, Open-label Study to Assess Corneal Endothelial Cells in Patients With Neovascular Age-related Macular Degeneration Treated With the Port Delivery System With Ranibizumab (PDS) (Belvedere) No dispute reported 06/30/2026 1211645851
Principal investigator 1 Genentech, Inc. $15,860.00 10/01/2025 Non-covered Recipient Entity
RETINA GROUP INC
A Phase IV, Multicenter, Open-label Study to Assess Corneal Endothelial Cells in Patients With Neovascular Age-related Macular Degeneration Treated With the Port Delivery System With Ranibizumab (PDS) (Belvedere) No dispute reported 06/30/2026 1211645856
Principal investigator 1 Boehringer Ingelheim International GmbH $58.30 09/24/2025 Non-covered Recipient Entity
Retina Consultant Of Texas-Schertz Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220759215
Principal investigator 1 Boehringer Ingelheim International GmbH $299.70 09/24/2025 Non-covered Recipient Entity
Retina Consultant Of Texas-Schertz Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220759217
Principal investigator 1 Boehringer Ingelheim International GmbH $1,569.50 09/24/2025 Non-covered Recipient Entity
Retina Consultant Of Texas-Schertz Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220759219
Principal investigator 1 Boehringer Ingelheim International GmbH $313.20 09/24/2025 Non-covered Recipient Entity
Retina Consultant Of Texas-Schertz Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220759221
Principal investigator 1 Boehringer Ingelheim International GmbH $21.00 09/24/2025 Non-covered Recipient Entity
Retina Consultant Of Texas-Schertz Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220759223
Principal investigator 1 Boehringer Ingelheim International GmbH $4.27 09/24/2025 Non-covered Recipient Entity
Retina Consultant Of Texas-Schertz Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220759225
Principal investigator 1 Boehringer Ingelheim International GmbH $69.96 09/24/2025 Non-covered Recipient Entity
Retina Consultant Of Texas-Schertz Retina Center
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220759241
Principal investigator 1 Boehringer Ingelheim International GmbH $219.78 09/24/2025 Non-covered Recipient Entity
Retina Consultant Of Texas-Schertz Retina Center
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220759243
Principal investigator 1 Boehringer Ingelheim International GmbH $255.50 09/24/2025 Non-covered Recipient Entity
Retina Consultant Of Texas-Schertz Retina Center
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220759245
Principal investigator 1 Boehringer Ingelheim International GmbH $5.00 09/24/2025 Non-covered Recipient Entity
Retina Consultant Of Texas-Schertz Retina Center
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220759247
Principal investigator 1 Boehringer Ingelheim International GmbH $93.28 09/24/2025 Non-covered Recipient Entity
Retina Consultant Of Texas-Schertz Retina Center
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220759249
Principal investigator 1 Boehringer Ingelheim International GmbH $159.84 09/24/2025 Non-covered Recipient Entity
Retina Consultant Of Texas-Schertz Retina Center
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220759251
Principal investigator 1 Boehringer Ingelheim International GmbH $547.50 09/24/2025 Non-covered Recipient Entity
Retina Consultant Of Texas-Schertz Retina Center
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220759253
Principal investigator 1 Boehringer Ingelheim International GmbH $146.16 09/24/2025 Non-covered Recipient Entity
Retina Consultant Of Texas-Schertz Retina Center
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220759255
Principal investigator 1 Boehringer Ingelheim International GmbH $3.66 09/24/2025 Non-covered Recipient Entity
Retina Consultant Of Texas-Schertz Retina Center
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220759257
Principal investigator 1 Genentech, Inc. $8,070.00 09/24/2025 Non-covered Recipient Entity
BROWN RETINA INSTITUTE
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211582093
Principal investigator 1 Genentech, Inc. $2,545.24 09/24/2025 Non-covered Recipient Entity
BROWN RETINA INSTITUTE
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211582097
Principal investigator 1 Genentech, Inc. $85.98 09/24/2025 Non-covered Recipient Entity
BROWN RETINA INSTITUTE
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211582101
Principal investigator 1 Genentech, Inc. $2,348.25 09/24/2025 Non-covered Recipient Entity
BROWN RETINA INSTITUTE
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211582104
Principal investigator 1 Genentech, Inc. $1,932.24 09/24/2025 Non-covered Recipient Entity
BROWN RETINA INSTITUTE
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211582113
Principal investigator 1 Hoffmann-La Roche Limited $3,300.00 09/24/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON
A Phase I, Multi-center, Multi-part Study to Investigate Safety, Tolerability, PK, PD, and Immunogenicity of RO7669330 Intravitreal Injections in Participants With GA Secondary to AMD: Part 1A: Open-label, MAD; Part 1B: Randomized PD Pilot; Part 2: Masked, Randomized, Active-comparator-controlled No dispute reported 06/30/2026 1211644381
Principal investigator 1 Hoffmann-La Roche Limited $790.00 09/24/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON
A Phase I, Multi-center, Multi-part Study to Investigate Safety, Tolerability, PK, PD, and Immunogenicity of RO7669330 Intravitreal Injections in Participants With GA Secondary to AMD: Part 1A: Open-label, MAD; Part 1B: Randomized PD Pilot; Part 2: Masked, Randomized, Active-comparator-controlled No dispute reported 06/30/2026 1211644398
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 09/24/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184242303
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $162.00 09/24/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184242305
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 09/24/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184242307
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.25 09/24/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184242309
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $162.00 09/24/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184242311
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $510.00 09/22/2025 Non-covered Recipient Entity
Rctx-Texas Medical Center Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220803304
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $373.00 09/22/2025 Non-covered Recipient Entity
Rctx-Texas Medical Center Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220803306
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $223.70 09/22/2025 Non-covered Recipient Entity
Rctx-Texas Medical Center Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220803308
Principal investigator 1 Genentech, Inc. $25,202.00 09/19/2025 Non-covered Recipient Entity
BROWN RETINA INSTITUTE
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211582081
Principal investigator 1 Genentech, Inc. $2,570.65 09/19/2025 Non-covered Recipient Entity
BROWN RETINA INSTITUTE
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211582109
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 09/17/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184238668
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 09/17/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184238670
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 09/17/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184238672
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 09/17/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184238674
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 09/17/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184238676
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 09/17/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184238678
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 09/17/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184238680
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 09/17/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184238682
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 09/17/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184238684
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 09/17/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184238686
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 09/17/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184238688
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 09/17/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184238690
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 09/17/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184238692
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 09/17/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184238694
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $15,000.00 09/15/2025 Non-covered Recipient Entity
Rctx-Texas Medical Center Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220803290
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $169.28 09/15/2025 Non-covered Recipient Entity
Rctx-Texas Medical Center Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220803292
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 09/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184236333
Principal investigator 1 Genentech, Inc. $249.00 09/10/2025 Non-covered Recipient Entity
BROWN RETINA INSTITUTE
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211582085
Principal investigator 1 Genentech, Inc. $3,038.00 09/10/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON PLLC RETINA CONSULTANTS OF TEXAS
Constance Faricimab in nAMD patients No dispute reported 06/30/2026 1211644763
Principal investigator 1 Genentech, Inc. $21,367.00 09/05/2025 Non-covered Recipient Entity
BROWN RETINA INSTITUTE
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211582089
Principal investigator 1 Boehringer Ingelheim International GmbH $5.67 09/04/2025 Non-covered Recipient Entity
Retina Consultant Of Texas-Schertz Retina Center
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220759259
Principal investigator 1 Boehringer Ingelheim International GmbH $5.67 09/04/2025 Non-covered Recipient Entity
Retina Consultant Of Texas-Schertz Retina Center
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220759261
Principal investigator 1 Boehringer Ingelheim International GmbH $40.13 09/04/2025 Non-covered Recipient Entity
Retina Consultant Of Texas-Schertz Retina Center
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220759263
Principal investigator 1 Boehringer Ingelheim International GmbH $15.69 09/04/2025 Non-covered Recipient Entity
Retina Consultant Of Texas-Schertz Retina Center
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220759265
Principal investigator 1 Boehringer Ingelheim International GmbH $15.40 09/04/2025 Non-covered Recipient Entity
Retina Consultant Of Texas-Schertz Retina Center
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220759267
Principal investigator 1 Boehringer Ingelheim International GmbH $16.77 09/04/2025 Non-covered Recipient Entity
Retina Consultant Of Texas-Schertz Retina Center
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220759269
Principal investigator 1 Boehringer Ingelheim International GmbH $20.51 09/04/2025 Non-covered Recipient Entity
Retina Consultant Of Texas-Schertz Retina Center
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220759271
Principal investigator 1 ABBVIE INC. $3,465.18 09/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON PLLC
Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy (RGX-314 SRLTFU) No dispute reported 06/30/2026 1202507059
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 09/01/2025 Non-covered Recipient Entity
Retina Consultant Of Texas-Schertz Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220759189
Recipient F. Hoffmann-La Roche AG $565.91 08/29/2025 Covered Recipient Physician Treatment Response and Safety of Faricimab in Underrepresented Patients With DME: Year 1 Results From ELEVATUM in the US No dispute reported 06/30/2026 1211536508
Principal investigator 1 ABBVIE INC. $194.40 08/27/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON PLLC
Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy No dispute reported 06/30/2026 1202506143
Principal investigator 1 ABBVIE INC. $851.71 08/27/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON PLLC
Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy No dispute reported 06/30/2026 1202506145
Principal investigator 1 ABBVIE INC. $2,589.17 08/27/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON PLLC
Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy No dispute reported 06/30/2026 1202506155
Principal investigator 1 F. Hoffmann-La Roche AG $1,463.00 08/22/2025 Non-covered Recipient Entity
Retina Consultants of Houston d/b/a Retina Consultants of Texas
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211644454
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $255.00 08/21/2025 Non-covered Recipient Entity
Rctx-Texas Medical Center Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220803282
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,000.00 08/21/2025 Non-covered Recipient Entity
Rctx-Texas Medical Center Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220803284
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,000.00 08/21/2025 Non-covered Recipient Entity
Rctx-Texas Medical Center Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220803286
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $487.00 08/21/2025 Non-covered Recipient Entity
Rctx-Texas Medical Center Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220803288
Principal investigator 1 Boehringer Ingelheim International GmbH $70.00 08/19/2025 Non-covered Recipient Entity
Retina Consultant Of Texas-Schertz Retina Center
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220759273
Principal investigator 1 Boehringer Ingelheim International GmbH $70.00 08/19/2025 Non-covered Recipient Entity
Retina Consultant Of Texas-Schertz Retina Center
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220759275
Principal investigator 1 Genentech, Inc. $193.00 08/19/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON PLLC RETINA CONSULTANTS OF TEXAS
Constance Faricimab in nAMD patients No dispute reported 06/30/2026 1211644756
Principal investigator 1 Genentech, Inc. $46,545.00 08/15/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON PLLC RETINA CONSULTANTS OF TEXAS
Constance Faricimab in nAMD patients No dispute reported 06/30/2026 1211644760
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $115.66 08/13/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184227121
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/13/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184227567
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/13/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184227569
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 08/13/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184227581
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 08/13/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184227593
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 08/13/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184227595
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 08/13/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184227597
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 08/13/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184227599
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/13/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184227611
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/13/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184227613
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/13/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184227615
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/13/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184227617
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/13/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184227619
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/13/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184227621
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/13/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184227623
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/13/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184227625
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 08/06/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184224352
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 08/06/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184224354
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 08/06/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184224356
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 08/06/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184224358
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 08/06/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184224360
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 08/06/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184224362
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 08/06/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184224364
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 08/06/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184224366
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 08/06/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184224382
Principal investigator 1 Apellis Pharmaceuticals, Inc. $325.00 08/01/2025 Non-covered Recipient Entity
Retina Consultants of Houston, PLLC
An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD No dispute reported 06/30/2026 1250363696
Principal investigator 1 Apellis Pharmaceuticals, Inc. $65.00 08/01/2025 Non-covered Recipient Entity
Retina Consultants of Houston, PLLC
An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD No dispute reported 06/30/2026 1250363702
Principal investigator 1 Apellis Pharmaceuticals, Inc. $2,225.00 08/01/2025 Non-covered Recipient Entity
Retina Consultants of Houston, PLLC
An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD No dispute reported 06/30/2026 1250363704
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 08/01/2025 Non-covered Recipient Entity
Retina Consultant Of Texas-Schertz Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220759187
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 07/31/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184222660
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 07/31/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184222662
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 07/31/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184222664
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 07/31/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184222666
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 07/31/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184222668
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 07/31/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184222670
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 07/31/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184222672
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 07/31/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184222674
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 07/31/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184222676
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 07/31/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184222678
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 07/31/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184222680
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 07/31/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184222682
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 07/31/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184222684
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $720.00 07/30/2025 Non-covered Recipient Entity
RETINA GROUP INC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184222218
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,680.00 07/30/2025 Non-covered Recipient Entity
RETINA GROUP INC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184222220
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $504.00 07/30/2025 Non-covered Recipient Entity
RETINA GROUP INC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184222222
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $882.00 07/30/2025 Non-covered Recipient Entity
RETINA GROUP INC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184222224
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $474.00 07/30/2025 Non-covered Recipient Entity
RETINA GROUP INC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184222226
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,205.00 07/30/2025 Non-covered Recipient Entity
RETINA GROUP INC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184222228
Principal investigator 1 Boehringer Ingelheim International GmbH $199.80 07/28/2025 Non-covered Recipient Entity
Retina Consultant Of Texas-Schertz Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220759213
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $73.82 07/28/2025 Non-covered Recipient Entity
Rctx-Texas Medical Center Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220803278
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $84.17 07/28/2025 Non-covered Recipient Entity
Rctx-Texas Medical Center Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220803280
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 07/16/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184215736
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 07/16/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184215740
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 07/16/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184215742
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 07/16/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184215744
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 07/16/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184215746
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 07/16/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184215748
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 07/16/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184215750
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 07/16/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184215752
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 07/16/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184215754
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 07/16/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184215758
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 07/16/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184215760
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 07/16/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184215762
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 07/16/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184215764
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 07/16/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184215766
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 07/16/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184215768
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 07/16/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184215770
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 07/16/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184215774
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 07/16/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184215776
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 07/16/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184215778
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 07/16/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184215780
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 07/16/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184215782
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 07/16/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184215784
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 07/16/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184215786
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 07/16/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184215790
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 07/16/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184215792
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $107.85 07/16/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184215794
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 07/16/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184215796
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 07/16/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184215798
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 07/16/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184215802
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 07/16/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184215804
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 07/16/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184215806
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 07/16/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184215808
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 07/16/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184215810
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 07/16/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184215812
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 07/16/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184215814
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $703.35 07/11/2025 Non-covered Recipient Entity
Rctx-Texas Medical Center Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220803276
Principal investigator 1 Genentech, Inc. $13,054.00 07/10/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON PLLC RETINA CONSULTANTS OF TEXAS
Constance Faricimab in nAMD patients No dispute reported 06/30/2026 1211644736
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 07/10/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184213650
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 07/10/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184213652
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $12,300.00 07/09/2025 Non-covered Recipient Entity
Rctx-Texas Medical Center Retina Center
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220803520
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $23.75 07/09/2025 Non-covered Recipient Entity
Rctx-Texas Medical Center Retina Center
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220803522
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 07/01/2025 Non-covered Recipient Entity
Retina Consultant Of Texas-Schertz Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220759181
Principal investigator 1 Boehringer Ingelheim International GmbH $24.94 07/01/2025 Non-covered Recipient Entity
Retina Consultant Of Texas-Schertz Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220759183
Principal investigator 1 Boehringer Ingelheim International GmbH $43.00 07/01/2025 Non-covered Recipient Entity
Retina Consultant Of Texas-Schertz Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220759185
Principal investigator 1 Genentech, Inc. $25.00 07/01/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON
A Phase 1 SAD MD in Diabetic Macular Edema No dispute reported 06/30/2026 1211644312
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $149.96 06/19/2025 Non-covered Recipient Entity
Retina Consultant Of Texas-Schertz Retina Center
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220813123
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $113.00 06/18/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184207621
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $203.00 06/18/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184207643
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $474.00 06/18/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184207783
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $504.00 06/18/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184207833
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $720.00 06/18/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184207925
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $882.00 06/18/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184208045
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,000.00 06/18/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184208089
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,680.00 06/18/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184208595
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,000.00 06/18/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184208751
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,300.00 06/18/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184208825
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 06/18/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184208891
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 06/18/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184208893
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 06/18/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184208895
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 06/18/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184208897
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 06/18/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184208957
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 06/18/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184208959
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $101.00 06/18/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184208963
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $338.00 06/09/2025 Non-covered Recipient Entity
Rctx-Texas Medical Center Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220803272
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $39.05 06/09/2025 Non-covered Recipient Entity
Rctx-Texas Medical Center Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220803274
Principal investigator 1 Apellis Pharmaceuticals, Inc. $3,911.40 06/06/2025 Non-covered Recipient Entity
Retina Consultants of Houston, PLLC
An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD No dispute reported 06/30/2026 1250363678
Principal investigator 1 Apellis Pharmaceuticals, Inc. $844.00 06/04/2025 Non-covered Recipient Entity
Retina Consultants of Houston, PLLC
An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD No dispute reported 06/30/2026 1250363670
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $170.00 06/04/2025 Non-covered Recipient Entity
Rctx-Texas Medical Center Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220803270
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 06/04/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184203039
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 06/04/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184203041
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 06/04/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184203043
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 06/04/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184203045
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 06/04/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184203047
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 06/04/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184203049
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 06/04/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184203051
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 06/04/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184203053
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 06/04/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184203055
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 06/04/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184203057
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 06/04/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184203059
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,025.00 06/03/2025 Non-covered Recipient Entity
Rctx-Texas Medical Center Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220803262
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,025.00 06/03/2025 Non-covered Recipient Entity
Rctx-Texas Medical Center Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220803264
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $14,750.00 06/03/2025 Non-covered Recipient Entity
Rctx-Texas Medical Center Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220803266
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,000.00 06/03/2025 Non-covered Recipient Entity
Rctx-Texas Medical Center Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220803268
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 06/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184202059
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 06/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184202061
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 06/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184202063
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 06/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184202065
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 06/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184202067
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 06/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184202069
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 06/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184202071
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 06/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184202073
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 06/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184202455
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 06/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184202457
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 06/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184202459
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 06/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184202745
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 06/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184202747
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 06/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184202749
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 06/01/2025 Non-covered Recipient Entity
Retina Consultant Of Texas-Schertz Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220759201
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $58.86 05/29/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184200227
Principal investigator 1 Boehringer Ingelheim International GmbH $19.00 05/27/2025 Non-covered Recipient Entity
Retina Consultant Of Texas-Schertz Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220759177
Principal investigator 1 Boehringer Ingelheim International GmbH $174.90 05/27/2025 Non-covered Recipient Entity
Retina Consultant Of Texas-Schertz Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220759179
Principal investigator 1 Boehringer Ingelheim International GmbH $179.82 05/27/2025 Non-covered Recipient Entity
Retina Consultant Of Texas-Schertz Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220759203
Principal investigator 1 Boehringer Ingelheim International GmbH $182.50 05/27/2025 Non-covered Recipient Entity
Retina Consultant Of Texas-Schertz Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220759205
Principal investigator 1 Boehringer Ingelheim International GmbH $39.44 05/27/2025 Non-covered Recipient Entity
Retina Consultant Of Texas-Schertz Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220759207
Principal investigator 1 Boehringer Ingelheim International GmbH $6.00 05/27/2025 Non-covered Recipient Entity
Retina Consultant Of Texas-Schertz Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220759209
Principal investigator 1 Boehringer Ingelheim International GmbH $1.22 05/27/2025 Non-covered Recipient Entity
Retina Consultant Of Texas-Schertz Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220759211
Principal investigator 1 Genentech, Inc. $3,605.00 05/14/2025 Non-covered Recipient Entity
BROWN RETINA INSTITUTE
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211582044
Principal investigator 1 Genentech, Inc. $3,184.00 05/14/2025 Non-covered Recipient Entity
BROWN RETINA INSTITUTE
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211582048
Principal investigator 1 Genentech, Inc. $2,043.00 05/14/2025 Non-covered Recipient Entity
BROWN RETINA INSTITUTE
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211582051
Principal investigator 1 Genentech, Inc. $987.00 05/14/2025 Non-covered Recipient Entity
BROWN RETINA INSTITUTE
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211582060
Principal investigator 1 Genentech, Inc. $612.00 05/14/2025 Non-covered Recipient Entity
BROWN RETINA INSTITUTE
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211582068
Principal investigator 1 Genentech, Inc. $613.01 05/14/2025 Non-covered Recipient Entity
BROWN RETINA INSTITUTE
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211582072
Principal investigator 1 Genentech, Inc. $371.00 05/14/2025 Non-covered Recipient Entity
BROWN RETINA INSTITUTE
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211582077
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184193059
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184193061
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184193063
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184193065
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184193067
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184193069
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184193071
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184193073
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 05/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184193075
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184193077
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184193079
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184193081
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 05/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184193083
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 05/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184193085
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184193087
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184193089
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184193091
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 05/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184193093
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 05/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184193095
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 05/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184193097
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 05/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184193099
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184193101
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184193103
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184193105
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184193107
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 05/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184193109
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 05/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184193201
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184193203
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184193205
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184193207
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 05/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184193209
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 05/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184193211
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184193213
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184193215
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 05/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184193217
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184193219
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 05/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184193221
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 05/01/2025 Non-covered Recipient Entity
Retina Consultant Of Texas-Schertz Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220759199
Principal investigator 1 Apellis Pharmaceuticals, Inc. $844.00 04/30/2025 Non-covered Recipient Entity
Retina Consultants of Houston, PLLC
An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD No dispute reported 06/30/2026 1250363654
Principal investigator 1 Genentech, Inc. $796.65 04/25/2025 Non-covered Recipient Entity
BROWN RETINA INSTITUTE
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211582055
Principal investigator 1 Genentech, Inc. $2,600.19 04/25/2025 Non-covered Recipient Entity
BROWN RETINA INSTITUTE
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211582064
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,225.85 04/23/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184187647
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 04/23/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184187649
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,225.85 04/23/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184187651
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 04/23/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184187653
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 04/23/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184187655
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 04/23/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184187657
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 04/23/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184187659
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,225.85 04/23/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184187661
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 04/23/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184187663
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 04/23/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184187665
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 04/23/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184187667
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 04/23/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184187669
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 04/23/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184187671
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,225.85 04/23/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184187673
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 04/23/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184187675
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,225.85 04/23/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184187677
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 04/23/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184187679
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 04/23/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184187681
Principal investigator 1 Genentech, Inc. $5,400.00 04/04/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON PLLC RETINA CONSULTANTS OF TEXAS
Not supplied No dispute reported 06/30/2026 1211645468
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $239.30 04/03/2025 Non-covered Recipient Entity
Retina Consultant Of Texas-Schertz Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220813121
Principal investigator 1 Apellis Pharmaceuticals, Inc. $3,672.00 04/02/2025 Non-covered Recipient Entity
Retina Consultants of Houston, PLLC
An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD No dispute reported 06/30/2026 1250363640
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 04/01/2025 Non-covered Recipient Entity
Retina Consultant Of Texas-Schertz Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220759197
Recipient F. Hoffmann-La Roche AG $607.27 03/31/2025 Covered Recipient Physician Treatment Response and Safety of Faricimab in Underrepresented Patients With DME: Year 1 Results From ELEVATUM in the US No dispute reported 06/30/2026 1211536513
Recipient F. Hoffmann-La Roche AG $6,502.00 03/31/2025 Covered Recipient Physician Treatment Response and Safety of Faricimab in Underrepresented Patients With DME: Year 1 Results From ELEVATUM in the US No dispute reported 06/30/2026 1211536516
Recipient F. Hoffmann-La Roche AG $607.27 03/31/2025 Covered Recipient Physician Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211536521
Principal investigator 1 Genentech, Inc. $949.00 03/26/2025 Non-covered Recipient Entity
BROWN RETINA INSTITUTE
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211582033
Principal investigator 1 Genentech, Inc. $5,400.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON PLLC RETINA CONSULTANTS OF TEXAS
Not supplied No dispute reported 06/30/2026 1211645465
Principal investigator 1 Boehringer Ingelheim International GmbH $7.44 03/25/2025 Non-covered Recipient Entity
Retina Consultant Of Texas-Schertz Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220759175
Principal investigator 1 Boehringer Ingelheim International GmbH $69.96 03/25/2025 Non-covered Recipient Entity
Retina Consultant Of Texas-Schertz Retina Center
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220759233
Principal investigator 1 Boehringer Ingelheim International GmbH $319.68 03/25/2025 Non-covered Recipient Entity
Retina Consultant Of Texas-Schertz Retina Center
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220759235
Principal investigator 1 Boehringer Ingelheim International GmbH $328.50 03/25/2025 Non-covered Recipient Entity
Retina Consultant Of Texas-Schertz Retina Center
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220759237
Principal investigator 1 Boehringer Ingelheim International GmbH $7.00 03/25/2025 Non-covered Recipient Entity
Retina Consultant Of Texas-Schertz Retina Center
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220759239
Principal investigator 1 Genentech, Inc. $35,218.00 03/21/2025 Non-covered Recipient Entity
BROWN RETINA INSTITUTE
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211582041
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184171378
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184171380
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184171382
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184171384
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184171386
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184171388
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184171390
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184171392
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184171394
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184171396
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184171398
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184171400
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184173666
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184173668
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184173670
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184173678
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184173680
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184173682
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184173690
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184173702
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184173724
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184173726
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,225.85 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184173728
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,225.85 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184173730
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,225.85 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184173732
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,225.85 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184173738
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184173740
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184173742
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/05/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184156955
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/05/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184156957
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/05/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184156959
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 03/01/2025 Non-covered Recipient Entity
Retina Consultant Of Texas-Schertz Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220759195
Recipient Regeneron Pharmaceuticals, Inc. $408.07 03/01/2025 Covered Recipient Physician A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184115881
Recipient Regeneron Pharmaceuticals, Inc. $150.00 03/01/2025 Covered Recipient Physician A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184115883
Recipient Regeneron Pharmaceuticals, Inc. $81.75 03/01/2025 Covered Recipient Physician A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184115885
Recipient Regeneron Pharmaceuticals, Inc. $21.80 03/01/2025 Covered Recipient Physician A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184115887
Recipient Regeneron Pharmaceuticals, Inc. $79.00 03/01/2025 Covered Recipient Physician A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184115889
Recipient Regeneron Pharmaceuticals, Inc. $21.80 03/01/2025 Covered Recipient Physician A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184115891
Recipient Regeneron Pharmaceuticals, Inc. $572.00 02/28/2025 Covered Recipient Physician A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184115877
Recipient Regeneron Pharmaceuticals, Inc. $184.25 02/28/2025 Covered Recipient Physician A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184115879
Principal investigator 1 Genentech, Inc. $951.00 02/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON
A Phase 1 SAD MD in Diabetic Macular Edema No dispute reported 06/30/2026 1211644225
Principal investigator 1 Boehringer Ingelheim International GmbH $46.64 02/25/2025 Non-covered Recipient Entity
Retina Consultant Of Texas-Schertz Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220759163
Principal investigator 1 Boehringer Ingelheim International GmbH $139.86 02/25/2025 Non-covered Recipient Entity
Retina Consultant Of Texas-Schertz Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220759165
Principal investigator 1 Boehringer Ingelheim International GmbH $365.00 02/25/2025 Non-covered Recipient Entity
Retina Consultant Of Texas-Schertz Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220759167
Principal investigator 1 Boehringer Ingelheim International GmbH $85.84 02/25/2025 Non-covered Recipient Entity
Retina Consultant Of Texas-Schertz Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220759169
Principal investigator 1 Boehringer Ingelheim International GmbH $9.00 02/25/2025 Non-covered Recipient Entity
Retina Consultant Of Texas-Schertz Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220759171
Principal investigator 1 Boehringer Ingelheim International GmbH $1.83 02/25/2025 Non-covered Recipient Entity
Retina Consultant Of Texas-Schertz Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220759173
Principal investigator 1 F. Hoffmann-La Roche AG $87.50 02/19/2025 Non-covered Recipient Entity
Retina Consultants of Houston d/b/a Retina Consultants of Texas
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211644450
Principal investigator 1 Genentech, Inc. $156.00 02/07/2025 Non-covered Recipient Entity
BROWN RETINA INSTITUTE
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211582022
Principal investigator 1 Genentech, Inc. $1,243.00 02/07/2025 Non-covered Recipient Entity
BROWN RETINA INSTITUTE
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211582025
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,500.00 02/05/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184152400
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 02/01/2025 Non-covered Recipient Entity
Retina Consultant Of Texas-Schertz Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220759193
Principal investigator 1 Genentech, Inc. $49.00 01/24/2025 Non-covered Recipient Entity
BROWN RETINA INSTITUTE
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211582019
Principal investigator 1 Genentech, Inc. $15,098.50 01/24/2025 Non-covered Recipient Entity
BROWN RETINA INSTITUTE
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211582029
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 01/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184146973
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 01/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184146975
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 01/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184146977
Principal investigator 1 Genentech, Inc. $24,076.00 01/03/2025 Non-covered Recipient Entity
BROWN RETINA INSTITUTE
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211582037
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 01/01/2025 Non-covered Recipient Entity
Retina Consultant Of Texas-Schertz Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220759191

Ownership and Investment Interests

One row per program year and measure, newest year first · the amount invested and the value of the interest are never added together

Program yearMeasureAmountRecords
PY2022 Amount invested $0.00 1
PY2022 Value of interest $30,000.00 1
PY2021 Amount invested $0.00 1
PY2021 Value of interest $30,000.00 1
PY2020 Amount invested $0.00 1
PY2020 Value of interest $30,000.00 1
PY2019 Amount invested $0.00 1
PY2019 Value of interest $30,000.00 1

Ownership and Investment Interests are a separate CMS dataset, shown here separately and never added to payments.

Ownership and investment interests are reported as the value of an interest held, not as a payment received. They are a different measure from the payment total on this page and are never combined with it.

Ownership and Investment Interests records

Ordering applied by this site (program year, newest first, then company) · record values are shown as CMS published them

4 records · PY2019–2022

Ownership and Investment Interests records (CSV)

Program yearCompanyAmount invested Value of interestTerms of interestInterest held by Dispute statusPublishedRecord ID
PY2022 US Retina LLC $0.00 $30,000.00 Shares Physician Covered Recipient No dispute reported 06/30/2026 951869571
PY2021 US Retina LLC $0.00 $30,000.00 Shares Physician Covered Recipient No dispute reported 06/30/2026 856668955
PY2020 US Retina LLC $0.00 $30,000.00 Shares Physician Covered Recipient No dispute reported 06/30/2026 714311255
PY2019 US Retina LLC $0.00 $30,000.00 Shares Physician Covered Recipient No dispute reported 06/30/2026 655842679